AtriCure's (ATRC) Amaze Trial Represents a Significant Opportunity, Needham Frames the Importance and Timelines
Tweet Send to a Friend
Needham & Company analyst Mike Matson reiterated a Buy rating and $91.00 price target on AtriCure Inc. (NASDAQ: ATRC) ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
